Applied DNA Sciences Signs $3 Million Exclusive Licensing Agreement for the United Kingdom.

Business Editors

LOS ANGELES--(BUSINESS WIRE)--Sept. 29, 2003

- Company launches first phase of international licensing strategy for line of proprietary DNA-security products to battle the rising tide of counterfeit goods in foreign markets -

Applied DNA Sciences, Inc. (OTCBB:APDN), a provider of proprietary DNA-embedded security solutions that protect corporate and intellectual property from counterfeiting and fraud, has signed an exclusive licensing agreement with London-based GA Corporate Finance, Ltd., a pan-European mergers and acquisitions and corporate finance advisory firm, for exclusive rights to sell Applied DNA Sciences' anti-counterfeit and fraud prevention products and services throughout the United Kingdom. The agreement, which has sales performance guarantees, will bring $3 million in revenue to the company, in addition to 20 percent of the gross sales of products and other revenue derived in the UK market.

The Imaging Supplies Coalition (ISC), a non-profit trade association comprised of original equipment manufacturers of consumable imaging supplies and equipment that have joined together to protect their customers by combating illegal activities in the Imaging Supplies Industry, estimates that global losses from counterfeiting and fraud range from 350 billion to one trillion USD per year. EU customs statistics for 2001 confirm that more than 94 million pirate and counterfeit articles were seized at borders, an increase of 39 percent compared with the year 2000. According to studies carried out by the International Chamber of Commerce, counterfeits accounted for 5 to 7 percent of world trade (approximately 250 billion Euros per year) and were responsible for the loss of over 200,000 jobs in Europe.

"There is a tremendous need for Applied DNA Sciences' anti-counterfeit technology and products in the UK. This licensing agreement is a great opportunity for our team to provide this exclusive technology to corporations and governments throughout the UK to address the dramatic rise in counterfeiting and fraudulent crime," said Baron von Nidda, chief executive officer of GA Corporate Finance, Ltd. "I am confident that the UK community will respond favorably to the Applied DNA product line."

Applied DNA Sciences' Chief Executive Officer Larry Lee said, "This is the first in a series of global licensing agreements that we are negotiating in foreign markets. It gives us an opportunity to aggressively roll out sales and marketing teams throughout the United Kingdom, generating awareness for our security solutions and products."

Applied DNA Sciences has an exclusive licensing and partnership agreement with Biowell Technology, Inc. of Taiwan with exclusive territories including North America and Europe. The company is positioned to be the market leader in sales, marketing, and sub-licensing of the DNA biotechnology products developed by Biowell in the world's largest markets.

In April 2003, the United States Department of Commerce selected Applied DNA Sciences' proprietary DNA-embedded textile marker system as one of three technologies that may allow for a cost-effective textile "marker" system for practical use by both U.S. textile manufacturers and the Customs Service. The selection was made at the recommendation of the Energy Department's Oak Ridge National Laboratory.

Applied DNA Sciences has developed a cost effective DNA-embedded ink technology that can protect brands or intellectual property from duplication and forgery. Applied DNA(TM) Ink is virtually impossible to replicate, and could be used in applications such as passports, visas, stocks, bonds, currency, pharmaceuticals, paintings, lottery tickets, sporting event tickets, etc. The company's Applied DNA(TM) Label application uses a proprietary instant-detection function that allows for real-time product authentication and can combat counterfeiting of clothing, jewelry, leather goods, art, wine, electronics, pharmaceuticals, food products, parts, nuclear waste, etc. Applied DNA(TM) Chip technology can be used in smart cards, passports, driver's licenses and semi-conductor boards. The DNA chip could also be integrated with other biometric solutions including fingerprint, facial and voice recognition technologies. The Applied DNA(TM) Security Access system uses the Applied DNA Chip in combination with molecular biotechnology and micro-engineering technology. The DNA chip and Security Access system allow for real-time authentication with a reader device.

About Applied DNA Sciences, Inc.

Applied DNA Sciences, Inc. provides proprietary DNA-embedded biotechnology security solutions, using non-human DNA, that verify authenticity and protect corporate and government agencies from counterfeiting, fraud, piracy, product diversion, identity theft and unauthorized intrusion. Applied DNA Sciences has an exclusive licensing and partnership agreement covering North America and Europe with Biowell Technology, Inc. (http://www.biowell.com.tw/eng) of Taiwan. The company develops, markets, and sub-licenses DNA security systems, supply-chain management systems and anti-counterfeit solutions. Applied DNA Sciences' technology addresses the more than $350 billion of counterfeit products sold each year as well as the multi-billion dollar homeland security market. The company is headquartered at 9255 West Sunset Boulevard, Los Angeles, CA 90069; Tel: [phone]; Fax: [phone] or visit www.ADNAS.com.

The statements made by Applied DNA Sciences, Inc. (the Company) may be forward-looking in nature and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe the Company's future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA Sciences, Inc. Actual results could differ materially from those projected due to changes in interest rates, market competition, changes in the local and national economies, and various other factors. The Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events.